SNAP-8 is sold in 10 mg vials. Its published human evidence is two cosmetic microneedle-patch studies that mixed it with other actives.

The molecule

An argireline with two more amino acids

SNAP-8 is a trademark for acetyl octapeptide-3, the eight-residue peptide Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2.[2] Argireline, or acetyl hexapeptide-8, is the six-residue Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2, described in 2002 and patterned on the N-terminal end of SNAP-25, a protein nerve endings need to release neurotransmitters.[6][7] Its developers presented it as a non-toxic peptide that emulates botulinum toxin, with much lower efficacy.[6]

The ingredient is sold to cosmetic formulators as a solution. A distributor's page for SNAP-8 peptide solution C says it is a Lipotec trademark, that the solution "contains 0.05% SNAP-8 powder," and that the recommended usage rate is 3 to 10% of a formula.[1] By pepmg's arithmetic, that puts the peptide at roughly 0.0015 to 0.005% of a finished cream. The same page warns not to apply the solution directly to the skin.[1] The Cosmetics Europe ingredient database lists acetyl octapeptide-3 as synthetic, with humectant and skin-conditioning functions.[17]

The distributor page also says that wrinkle severity around the eyes "decreased up to 63.13%" in clinical studies and that testing "suggests that SNAP-8 is approximately 30% more active" than argireline.[1] pepmg found no published study behind either number in its PubMed search, so both are manufacturer claims.[4]

Human studies of SNAP-8

Two patch studies, neither able to isolate the peptide

A PubMed search on November 4, 2026 for acetyl octapeptide-3, SNAP-8, Snap 8 or octapeptide-3 in titles and abstracts returned two records.[4] ClinicalTrials.gov listed no study for SNAP-8 or for "acetyl octapeptide" the same day.[5]

The 2024 study, from Korea, tested a dissolving microneedle patch made of 0.03% SNAP-8, 5% of a vitamin C derivative, 4% of a lysophosphatidic acid derivative and 90% hyaluronic acid, with 350 µm needles.[2] It enrolled 24 people aged 30 to 65 with eye wrinkles, and 21 completed it. Each wore the active patch by one eye and a hyaluronic acid-only patch by the other, nightly for 14 days and then every third day to day 28.[2] The authors report better wrinkle, skin-water-loss, elasticity and eye-lifting measurements on the active side and no adverse effects.[2] The paper does not describe randomization or blinding, the paper acknowledges support from Raphas, the patch maker with which four of the five authors are affiliated, and with three actives in the patch it cannot show what SNAP-8 contributed.[2]

The 2020 study tested a hyaluronic acid microneedle patch containing an arginine/lysine polypeptide, acetyl octapeptide-3, palmitoyl tripeptide-5, adenosine and seaweed extracts, applied by the eyes and on the forearm over 12 weeks. Its abstract reports a 25.8% decrease in fine lines and wrinkles and no skin reactions, but gives neither the number of participants nor a control group.[3] pepmg read only the abstract.

The parent peptide

Argireline: small topical trials and a skin barrier problem

The first argireline paper, in 2002, reported that an emulsion containing 10% of the hexapeptide reduced wrinkle depth in healthy women by up to 30% over 30 days; the abstract does not give the number of volunteers or describe a control group.[6] A 2013 randomized, placebo-controlled trial assigned 60 Chinese participants 3:1 to argireline or placebo, applied around the eyes twice daily for 4 weeks. Its abstract reports a subjective "total anti-wrinkle efficacy" of 48.9% with argireline against 0% with placebo, and objective roughness measurements that fell within the argireline group (p < 0.01) but not within the placebo group.[7] Those objective results are within-group changes, not a reported comparison between groups.

The trial of argireline as a medical treatment that pepmg found was negative. At the NIH, under an FDA investigational new drug application, 24 people with blepharospasm who were already receiving botulinum toxin were randomized to a 0.005% argireline cream or a matching placebo cream.[8] Time until symptoms returned to baseline was 3.7 months with argireline and 3.0 months with placebo, a trend the authors call not statistically significant; the primary outcome was negative.[8] The creams were made by BCN Peptides, part of Lipotec's group, and four participants had mild eyelid discomfort that occurred with both creams.[8]

Getting the peptide into skin is the open problem. In an FDA laboratory study using human cadaver skin, after 24 hours under a cream containing 10% argireline, most of the peptide washed off the surface, about 0.22% of the applied dose was in the outer stratum corneum, about 0.01% reached the epidermis and none was detected in the dermis or the fluid beneath it.[9] A 2025 review concludes that argireline's ability to reach the junctions between nerves and muscles "remains uncertain."[10] The Cosmetic Ingredient Review expert panel found argireline safe in cosmetics at concentrations up to 0.005%, and said the data are insufficient to decide safety above that.[11]

Newer human data still come as mixtures. A 2026 L'Oréal paper tested a serum combining argireline with four other actives in 50 and 42 participants, and its abstract does not describe a vehicle or placebo comparison.[14]

Injection

One published infection, one rat study, no human trial

pepmg found no human study that injected SNAP-8. For argireline, a 2021 case report describes a 45-year-old woman who had "a bottle of argireline (concentration unknown)" injected into her forehead and temples at a private cosmetic clinic.[12] A week later she developed redness, nodules and abscesses at the injection sites; cultures grew Mycobacterium abscessus, and the lesions resolved only after about five months of clarithromycin and moxifloxacin, leaving scars and pigmentation.[12] The authors suspected the drug, its solvent or the syringe was contaminated.[12] One case cannot show how often this happens, but it documents a serious infection after a cosmetic argireline injection.

The only injection experiment pepmg found was in animals. In a 2026 study in 40 female rats, subdermal argireline produced a dermal collagen profile indistinguishable from saline, and the authors conclude that "injectable Argireline produced no detectable tissue-level effect under the tested conditions."[13] No protocol was registered in advance.[13]

Status

A cosmetic ingredient, not an approved drug

pepmg found no FDA drug approval for SNAP-8 or argireline in Drugs@FDA, searched through openFDA on November 4, 2026.[19] Neither acetyl octapeptide-3, SNAP-8, argireline nor acetyl hexapeptide-8 appears in any category of FDA's 503A bulk substance nominations list, updated May 14, 2026.[15] pepmg did not check the 503B list.

FDA says whether a product is regulated as a cosmetic or a drug depends on its intended use, and that the law defines drugs to include "articles (other than food) intended to affect the structure or any function of the body."[16] pepmg does not decide how any listing would be classified.

The market

Vials, bulk powder and one cream

pepmg's November 3, 2026 index shows SNAP-8 at 42 vendors in 57 listings. Thirty-six are vials or kits of 5 to 20 mg, 27 of them 10 mg; 14 are 100 mg or more; six are named as raw powder; one is a blend with GHK-Cu ; and one is a 50 mL cream.[18] The published human studies tested the peptide at 0.03% inside a skin patch with other ingredients.[2] None tested a reconstituted vial, and none shows what a research-shelf product contains or does.

Questions people are asking